ProKidney Q3 net loss to Class A stockholders more than doubles to $35.59 million
PROK•ProKidney’s third-quarter 2026 net loss available to Class A common stockholders more than doubled year over year to $35.59 million, while revenue fell 20% to $174,000 and research and development expenses rose 52% to $40.85 million.
1. Quarterly results
ProKidney reported a third-quarter 2026 net loss available to Class A common stockholders of $35.59 million, more than double the year-earlier loss. Revenue fell 20% year over year to $174,000, and research and development expenses increased 52% to $40.85 million.
2. Cash and trial timing
Cash, cash equivalents and marketable securities totaled $141.9 million at September 30, supporting operations into mid-2027. Full enrollment in the pivotal Phase 3 PROACT 1 trial is expected in the first quarter of 2027, with eGFR-slope results still scheduled for the second quarter of 2027.
